Aortic Infections and Inflammations
Conditions
Brief summary
While surgery with anatomic reconstruction of prosthetic aortic infections and native infectious aortitis has become established over time, the ideal substitute is not clearly defined. The cryopreserved arterial allograft (AAC) recognized as resistant to infections not only presents availability problems making its use complicated, particularly in emergencies, with a certain number of long-term aneurysmal developments. The tubulized pericardium patch (PP), available in all cases, seems to give promising results in recent literature. The investigators propose a comparative study of these two substitutes in this indication. We carried out a two-center observational study including retrospectively from January 2010 to July 2023 all patients operated on for aortic prosthesis infection and native infectious aortitis with AAC reconstruction and prospectively PP patch reconstructions from July 2018 to July 2023. The diagnosis of infection was established according to the MAGIC criteria. The patients' preoperative comorbidities were collected to compare the groups. Postoperative morbidity and mortality was then compared. The medium-term evaluation consisted of comparing according to the Kaplan Meier method: postoperative mortality, permeability, reinfection rate, reoperation rate.
Interventions
PROCEDUREExplantation of a previous aortic graft or endograft and reconstruction by arterial allograft or rolled pericardium
In situ reconstruction with explantation of the infected graft or endograft and reconstruction by allograft or pericardium
Sponsors
LUCAS BATISTELLA, MD
Kheira hireche, MD
Ludovic CANAUD, MD PhD
University Paul Sabatier of Toulouse
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* All aortic intervention performed for native aortic infection reconstruction with patch or allograft * All aortic intervention performed for infected graft reconstruction with patch or allograft
Exclusion criteria
* no
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | day 30 post operative | Number of patients death during post operative stay |
| Reintervention | 30 days, 6 months, 12 months, 24 months | Rate of reintervention during post operative stay |
| Post operative Major cardiovascular adverse events (MACE) | day 30 post operative | Rate of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Permeability | 30 days, 6 months, 12 months, 24 months | Rate of reintervention for occlusion of the patch or the allograft |
| Reinfection | 30 days, 6 months, 12 months, 24 months | Rate of reintervention for infection of the patch or the allograft |
Outcome results
None listed